Analysing the compliance imperatives for both US pharma and the strategic considerations for Chinese biotech navigating the cross-border environment.
Carl Valenstein | Morgan Lewis
Several legislative proposals, actions, and regulations are underway in parallel, all at different stages of maturity and all subject to significant political uncertainty.
Non-US financial institutions are likely to evaluate Cuba-related customers or counterparties more strictly in light of the new secondary sanctions authority.